Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;33(2):92-97.
doi: 10.1055/s-0040-1701233. Epub 2020 Feb 25.

Fecal Microbiota Transplantation: Redefining Surgical Management of Refractory Clostridium difficile Infection

Affiliations
Review

Fecal Microbiota Transplantation: Redefining Surgical Management of Refractory Clostridium difficile Infection

Yao-Wen Cheng et al. Clin Colon Rectal Surg. 2020 Mar.

Abstract

Fecal microbiota transplantation (FMT) is the process of transplanting stool from a healthy donor into the gut of a diseased individual for therapeutic purposes. It has a clearly defined role in the treatment of recurrent Clostridium difficile (reclassified as " Clostridioides difficile ") infection (CDI), with cure rates over 90% and decreased rates of subsequent recurrence compared with anti-CDI antibiotics. There is emerging evidence that FMT is also effective in the treatment of severe and fulminant CDI, with associated decreases in mortality and colectomy rates compared with standard antibiotic therapy. FMT shows promise as salvage therapy for critically-ill CDI patients refractory to maximum medical therapy and not deemed to be surgical candidates. FMT should be considered early in the course of severe CDI and should be delivered immediately in patients with signs of refractory CDI. Expansion of FMT's use along the spectrum of CDI severity has potential to decrease associated rates of mortality and colectomy.

Keywords: Clostridium difficile; colectomy; colitis; colonoscopy; fecal microbiota transplantation; toxic megacolon.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Similar articles

Cited by

References

    1. Zhang F, Luo W, Shi Y, Fan Z, Ji G.Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012107111755, author reply 1755–1756 - PubMed
    1. Lawson P A, Citron D M, Tyrrell K L, Finegold S M. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938 . Anaerobe. 2016;40:95–99. - PubMed
    1. Khoruts A, Sadowsky M J. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016;13(09):508–516. - PMC - PubMed
    1. McFarland L V, Surawicz C M, Greenberg R N et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease . JAMA. 1994;271(24):1913–1918. - PubMed
    1. Chang J Y, Antonopoulos D A, Kalra A et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile -associated diarrhea . J Infect Dis. 2008;197(03):435–438. - PubMed